BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Keystone Biologicals, Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT’s disease-state portfolio both by volume and product range.
“With the addition of Keystone Biologicals, BioIVT broadens its product offerings and better supports clients in the in vitro diagnostic (IVD) market,” said BioIVT Chief Executive Officer Jeffrey Gatz. “This acquisition furthers our mission of becoming the partner of choice for both biopharmaceutical and diagnostic clients.”
“In BioIVT, we have found a like-minded partner whose desire to provide the highest quality research samples and customized products and services to satisfy client needs equals our own,” said Keystone Biologicals President Darren Lowenthal. “We are delighted to be joining BioIVT and look forward to working together for the benefit of all our clients.”
Keystone Biologicals provides a broad range of autoimmune, serology and virology, immunology, and tumor marker research samples. Its antibody positive cohorts include donors with infectious diseases such as hepatitis, herpes, syphilis and toxoplasmosis, and autoimmune diseases such as rheumatoid factor and systemic lupus. It also offers liquid-stable controls, standards and calibrators for use with stock or custom-produced diagnostic kits.
In addition, Keystone Biologicals’ in-house laboratory enables it to characterize raw material using a variety of testing formats including the client’s own test kits. By using clients’ own assays, Keystone Biologicals can help ensure that clients do not spend time and money evaluating material that does not meet their study requirements.
